ArticleBMC rheumatology2025
Maternal and neonatal outcomes in pregnancies with rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: a comparative study.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA), poses unique challenges during pregnancy due to potential maternal and fetal complications. This study aimed to compare pregnancy outcomes among women with these conditions in Qatar.
methodsA retrospective cohort study was conducted at Hamad General Hospital from 2016 to 2022. Data on sociodemographic characteristics, disease features (e.g., disease duration, serological markers), treatments, and pregnancy outcomes were extracted from electronic medical records. Pregnancy outcomes included miscarriage, live birth, and intrauterine fetal demise (IUFD); delivery data such as term, weeks of gestation, and mode of delivery; and neonatal data including birth weight, low birth weight (LBW), congenital anomalies, and NICU admissions. Multivariable logistic regression was used to identify associations between disease subtype, medication use, and pregnancy outcomes.
resultsA total of 189 pregnant women were included (RA = 131, SpA = 29, and PsA = 29). Pregnancy outcomes were compared across the three patient groups: SpA was associated with the highest live birth rate (89.7%), while PsA had the highest rate of NICU admissions (13.8%) and lowest preterm birth rate (6.9%). Intrauterine growth restriction (IUGR) occurred only in RA (31%). Multivariable analyses showed that SpA was linked to significantly higher odds of live birth and lower risks of miscarriage, peripartum complications, and low birth weight compared to RA. PsA was associated with a reduced risk of preterm birth. Advanced maternal age increases the risk of any complication taken together. Sulfasalazine use was associated with lower miscarriage risk and higher likelihood of live birth, but also increased NICU admissions, as did anti-TNF therapy. Hydroxychloroquine use was associated with a protective effect against NICU admissions and low birth weight.
conclusionPregnancy outcomes vary significantly across chronic inflammatory arthritis subtypes. Our findings underscore the need for individualized, multidisciplinary care and further prospective studies to guide clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.